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ABSTRACT  The usefulness of the Fractional exhaled nitric oxide (FeNO) measurements for 
asthma exacerbation risk prediction in asthmatic children is controversial. Fifty-seven asthmatic 
children who were regularly treated and had previously been stable for at least 3 months were 
enrolled. The asthma excerbations risk prediction by the FeNO levels and age contribution on 
it were investigated. As analyzed all the patients, FeNO cut off value for the significant risk 
of asthma exacerbation was 36.9 ppb (risk odds was 5.1 [95% C.I., 1.8 to 15.0], chi square 
valve = 9.0, p = 0.0028). However, sensitivity and specificity were not adequate for predicting 
asthma exacerbation (Sensitivity, 77.8%; Specificity, 59.9%; Area under the curve [AUC], 0.674). 
These parameters were improved only when 6-10 year old children were assessed (FeNO 
threshold=39.9 ppb, risk odds=10.2 [3.1 to 33.1], chi square valve 14.8, p=0.0001); Sensitivity, 
80.8%; Specificity, 71.8%; AUC, 0.758). High value of FeNO is a risk factor for the asthma 
exacerbation, and FeNO measurement may be more useful for asthma control in younger 
children than elder asthmatic children. doi：10.11482/KMJ-E40（1）41　(Accepted on December 24, 2013)
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INTRODUCTION
   Childhood bronchial asthma is a disease 
associated with wheezing during exacerbation and 
characterized by repeated episodes of dyspnea. The 
dyspnea in most cases is improved spontaneously 
or by treatment, otherwise, it can be fatal in rare 
cases. The persistent airway inflammation and 
remodeling are involved in the airflow limitation１）. 
Meansurement of fractional exhaled nitric oxide 
(FeNO), which is considered to reflect the 
eosinophilic airway inflammation, is simple and 
noninvasive and it can be performed easily even in 
children２, ３）. Asthma worsening and FeNO level in 
childhood bronchial asthma are correlated４－９）. 
   Four randomized controlled trials (RCTs) 
examined the usefulness of FeNO as a marker for 
childhood asthma control, however, these have 
shown different conclusions, an achievement of 
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favorable levels of bronchial hyper-responsiveness 
and forced expiratory volume in 1 second (FEV1) 
without increase of the inhaled corticosteroid (ICS) 
doses10）, no change in respiratory symptoms with 
increased ICS doses11，12）, or no change in either 
respiratory symptoms or ICS doses13）. Though no 
one can tell who will catch a cold beforehand, is it 
true if the airway inflammation level is higher, will 
the worsening of the asthma condition be increased? 
It might be difficult to predict asthma exarcebation 
by FeNO levels. For children, the impact of age 
should be considered, because the patterns of 
exacerbation are different between younger and 
elder children. 
   In the present study, we retrospectively examined 
if the high FeNO level is a significant risk factor of 
asthma exacerbation, divided by the age range.
METHODS
Subjects and methods
   Fifty seven children with bronchial asthma (38 
boys and 19 girls, range 6.0 to 15.0 years, median 
9.2 years) who regularly attended the Department 
of Pediatrics, Kawasaki Medical School Hospital 
between July 2008 and March 2012 were the 
subjects. Bronchial asthma had been diagnosed 
by confirming dyspnea accompanied by recurrent 
wheezing and treated according to the 2012 
Japanese Guidelines for Treatment and Control 
of Childhood Bronchial Asthma1） (Table 1). 
The association between a total of 161 FeNO 
measurements obtained from the patients with their 
asthma were well controlled at least 3 months and 
subsequent asthma exacerbation in 3 months was 
retrospectively examined. Asthma exacerbations 
were defined as apparent wheezing or dyspnea 
confirmed by the children themselves and/or 
members of their families, according to an asthma 
diary. The presence or absence of allergic rhinitis 
was confirmed by medical records and/or the 
comments of family members of children. Treatment 
steps (mild,2; moderate,3; severe,4) were defined 
by ICS dosage according to the Japanese guideline. 
An airway hyperreactivity test was performed to 
determine the bronchial hyperesponsiveness. This 
study was approved by the ethics committee of our 
institution (409-1), and written informed consent 
was obtained from the parents of all the participated 
children.
FeNO measurement
   FeNO levels were measured with the online 
method, using Nitric Oxide Analyzer NOA 280i 
(Sievers Instruments, Inc., Boulder, CO, USA). 
According to the guidelines recommended by 
the American Thoracic Society and European 
Respiratory Society, FeNO levels were measured in 
the resting-sitting position with conditions meeting 
respiratory resistance of 5-20 cm H2O from maximal 
inspiratory level, respiratory flow of 0.05 L/sec ± 
10%, and duration of at least 6 seconds2）. At least 3 
Table 1. Medication and treatment step of subjects
N 161
Treatment steps (/day)
Step. 2 48 (30%)
LTRA 28
ICS 100μg 13
ICS 100μg＋LTRA 7
Step. 3 54 (34%)
ICS 200μg 11
ICS 200μg＋ LTRA 17
SFC 50μg 1
SFC 100μg 19
SFC 100μg＋ LTRA 2
BIS 0.5 mg＋ LTRA 4
Step. 4 59 (36%)
ICS 400μg 7
ICS 400μg＋ LTRA 2
SFC 200μg 16
SFC 200μg＋ LTRA 23
SFC 250μg＋ LTRA 3
SFC 500μg＋ LTRA 5
BIS 1 mg 1
BIS 1 mg＋LTRA 2
   Treatment Steps are based on JPGL 2012
LTRA: leukotriene receptor anatagonist
ICS: inhaled corticosteroid
SFC: salmeterol/fluticasone combination
BIS: budesonide inhalation suspension
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measurements were conducted, and the mean within 
an error of 10% was used as the measurement result.
Airway hyperreactivity test
   Bronchodilators are withdrawn 12 hours before the 
airway hyperreactivity test, and anti-inflammatory 
drugs, such as ICS, and histamine H1 antagonists 
were withdrawn 24 hours before the test. Regarding 
the measurement procedure, FEV1 was first 
measured immediately before the test, and the 
value obtained was used as the reference FEV1. 
It should be confirmed that FEV1 measured after 
inhalation of physiological saline for 2 minutes was 
not decreased by 10% or more from the reference 
FEV1. Then, FEV1 was measured after inhalation 
of solutions containing various concentrations of 
acetylcholine for 2 minutes each, starting from 
the lowest concentration solution. The solution 
concentration at which the measured FEV1 was 
decreased by at least 20% was determined as PC20 
from single logarithmic charts. Less than 8 mg/
ml of PC20 was considered as positive bronchial 
hyperresponsiveness.
Statistical analysis
   The Mann-Whitney U and χ2 tests were used for 
comparisons of each factor between the 2 groups 
(with and without exacerbation), and the χ2 test 
and correlation analysis were used for analyzing 
other factors affecting FeNO levels. Moreover, the 
FeNO cut-off level for the prediction of asthma 
exacerbation was calculated employing a receiver 
operating characteristic (ROC) curve. The criterion 
for a statistically significant difference was p < 0.05.
RESULTS
   The mean (SD) FeNO was significantly higher in 
the children who had exacerbation within 3 months 
than those who did not (49.8 (24.1) vs. 37.0 (24.1) 
ppb, p = 0.017) (Table 2). Mean values of age, 
disease duration, ratio of male-to-female, the atopic 
status, concomitant allergic rhinitis, or severity at 
the time of measurement, or PC20 were not different 
between the groups (Table 2).
   The ROC curve analysis revealed that the best 
FeNO cut-off level suggested the significant 
increasing risk of asthma exacerbation was 36.9 ppb. 
The sensitivity, specificity, and area under the curve 
(AUC) were 77.8%, 59.9%, and 0.674, respectively, 
however none were considered to be sufficiently 
high for clinical application (Fig. 1). The risk odds 
of asthma exacerbation was 5.1 (95%C.I., 1.8 to 
15.0, chi square = 9.0, p = 0.0028).
   A positive correlation was observed between age 
and FeNO levels (p < 0.001, r = 0.326) (Fig. 2). 
There was no significant correlation between the 
duration of asthma and FeNO levels (p = 0.396, r = 
0.068). There was no significant difference in FeNO 
levels between children with and without allergic 
rhinitis (34.43 (23.86) vs. 42.24 (27.95) ppb, p = 
0.078).
   Because there was a significant correlation 
Table 2. Comparison of the characteristics between the 6-15 years old children with and without 
exacerbations in 3 months
With 
exacerbation
(n = 18)
Without
exacerbation
(n = 143)
P value
Age, years, mean (SD) 8.83 (2.00)  9.79 (2.36) 0.095 
Disease duration, year, mean (SD) 4.26 (2.29)  4.48 (2.29) 0.925
Sex (M/F) 13/5 87/56 0.445 
Atopic/non-atopic 17/1 132/11 0.740
Allergic rhinitis, yes (%) 9 (50) 77 (53) 0.758
Treatment step, Step 2/3/4 7/7/4 41/47/56 0.408
FeNO (ppb) 49.8 (24.1) 37.1 (24.1) 0.017
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between FeNO levels and age, the usefulness of 
FeNO for increasing risk of exacerbation was re-
examined by limiting the subjects to children 
between 6.0 and 10.0 years of age (a total of 100 
measurements) (Table 3). The FeNO levels were 
significantly higher in the children had exacerbation 
than those did not (49.9 (27.7) vs. 30.0 (22.6)ppb, p 
< 0.017). No significant differences were observed 
in any other factors. The ROC curve analysis 
revealed the best FeNO cut-off level for the asthma 
exacerbation risk to be 39.9 ppb. The sensitivity, 
specificity, and AUC were 80.8%, 71.8%, and 0.758, 
respectively, all of them were favorable (Fig. 3). The 
risk odds of asthma exacerbation was 10.2 (3.1 to 
33.1, chi square = 14.8, p = 0.0001).
Fig. 1.   ROC curve of FeNO for asthma exacerbation risk in 
6-15 year old patients.
The best FeNO cut-off value was 36.9 ppb (Sensitivity, 
77.8%; Specificity, 59.9%; AUC, 0.674; Risk Odds 5.1 [1.8 to 
15.0, chi square=9.0, p=0.0026]).
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Fig. 2.   Correlations between age and FeNO in asthmatic 
children.
There was a significant correlation between age and FeNO in 
asthmatic children (p < 0.001, r = 0.326).
Table 3. Comparison of the characteristics between the 6-10 years old children with and without 
exacerbation in 3 months
With
exacerbation
(n = 15)
Without
exacerbation
(n = 85)
P value
Age, years, mean (SD) 8.14 (1.11)  8.16 (1.16) 0.915 
Disease duration, year, mean (SD) 4.09 (2.48)  4.46 (1.90) 0.592
Sex (M/F) 11/4 57/28 0.631 
Atopic/non-atopic 14/1 74/11 0.491
Allergic rhinitis, yes (%) 8 (53) 43 (51) 0.845
Treatment step, Step 2/3/4 5/6/4 29/30/26 0.903
FeNO (ppb) 49.9 (27.7) 30.0 (22.6) < 0.001
㩷
Sensitivityᴾ
0.1ᴾ
0.2ᴾ
0.3ᴾ
0.4ᴾ
0.5ᴾ
0.6ᴾ
0.8ᴾ
0.9ᴾ
0.1ᴾ 0.2ᴾ 0.3ᴾ 0.4ᴾ 0.5ᴾ 0.6ᴾ 0.7ᴾ 0.8ᴾ 0.9ᴾ
1-Specificityᴾ
39.9 ppbᴾ
0.7ᴾ
Figure. 3ᴾ
Fig. 3.   ROC curve of FeNO for predicting asthma 
exacerbation in patients 6-10 years old.
The best FeNO cut-off value was 39.9 ppb (Sensitivity, 
80.0%; Specificity, 71.8%; AUC, 0.758; Risk Odds 10.17 [3.1 
to 33.1, chi square=14.8, p=0.0001]).
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DISCUSSION
   In this study, we found that high FeNO more 
than 36.9 ppb was a significant risk of asthma 
exacerbation in the following 3 months in children 
with stable bronchial asthma up to 5 times and this 
tendency was prevalent in the younger children (6 to 
10 years of age than 11 years or more). However, the 
sensitivity and specificity were not sufficiently high 
(77.8% and 59.9%, respectively). Because we found 
that FeNO levels correlated with age (p < 0.001, r 
= 0.326), the analysis was repeated by limiting the 
subjects to children between 6.0 and 10.0 years of 
age. The results suggested that higher FeNO was a 
more significant risk factor (10.2 times) for asthma 
exacerbation in 3 months in younger children. The 
sensitivity and specificity of the recalculated cut-off 
level (39.9ppb) were favorable at 80.0% and 71.8%, 
respectively. The patient age ranges were broad, 
from 6 to 18 years in two previous RCTs conducted 
by Marielle et al.9） or Fritsch et al. 10）, from 12 to 18 
years in an RCT conducted by Szifer et al.11）, and 
from 6 to 12 years in an RCT conducted by Jongste 
et al.12）, only in the latter RCT had different FeNO 
cut-off levels set: 20 ppb for the patients less than 10 
years of age versus 25 ppb for those aged 10 years 
and older. FeNO levels were reported to be higher 
in older children14）. Our study had shown similar 
results which was understandable. 
   Although FeNO can be a risk factor of asthma 
exacerbation in children before puberty, it might 
not be the same for pubertal patients. A similar 
indication was reported in a study that the airway 
hyperreactivity test could predict the course of 
asthma in children from 5 up to almost 11 years of 
age, but that it was difficult to predict the disease 
course in those between 12 and 16 years of age15）. 
The exact reason is not clear, however, we speculate 
that older children may possess more extensive 
reasons for asthma exacerbation.
   The first discrepancy of the study was that we 
did not find FeNO level differences between the 
children with and without allergic rhinitis (p=0.07). 
FeNO is elevated by not only bronchial asthma, but 
also viral infections16－18）, allergic rhinitis19）, and so 
on. Generally, bronchial asthma and allergy rhinitis 
are comorbid in about 80% each other20，21）, our 
subject asthma children had allergy rhinitis in only 
approximately 50%. This might affect the FeNO 
levels and threshold also. No difference in FeNO 
levels between asthmatic patients with and without 
hay fever was reported22）. The effect of allergic 
rhinitis on FeNO level is still controversial. The 
second inconclusive area  was that the study was not 
performed in a prospective manner. We should have 
planned a prospective study, but we were not aware 
the adequate subject number and follow up periods. 
Therefore, we are now planning a prospective 
comparative study which set cut-off value in 39.9 
according to this study results.
   In conclusion, our results suggest that FeNO 
measurement may be useful for the consideration 
of predicting asthma exacerbation risk and the 
increase of risk is more significant in pre-pubertal 
children. Additionally, we may have to pay attention 
to worsening of asthma symptoms when child with 
asthma has high FeNO level.
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